← Back to Clinical Trials
Recruiting NCT06307418

NCT06307418 Internet-based Support for Informal Caregivers of Patients With Head and Neck Cancer - Carer eSupport

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06307418
Status Recruiting
Phase
Sponsor Uppsala University
Condition Head and Neck Cancer
Study Type INTERVENTIONAL
Enrollment 110 participants
Start Date 2024-08-20
Primary Completion 2026-10-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Carer eSupport

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 110 participants in total. It began in 2024-08-20 with a primary completion date of 2026-10-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this randomized controlled trial is to investigate the effects of internet-based support (Carer eSupport) on preparedness for caregiving in informal caregivers of patients with head and neck cancer. The main question\[s\] it aims to answer are: * What are the effects of internet-based support on informal caregivers preparedness for caregiving? * What are the effects of internet-based support on informal caregivers burden and wellbeing? Informal caregivers who are randomized to Carer eSupport will have access to Carer eSupport for 18 weeks and they will be asked to complete questionnaires (outcome measures) at: * baseline (before randomization) * 18 weeks (post-intervention) and at * 3 months after the intervention is completed (long term follow-up). Informal caregivers in the intervention group will be compared to informal caregivers who receive standard care support regarding preparedness for caregiving, caregiver burden and wellbeing.

Eligibility Criteria

Inclusion Criteria: * Informal caregivers who have been identified as an informal caregiver by a patient who have consented to that the informal caregivers is approached. * Informal caregivers of patients with head and neck cancer who are about to start radiotherapy or have undergone at most five radiotherapy treatment session. Radiotherapy may be combined with surgery and/or medical oncological treatment. Exclusion Criteria: * Informal caregivers who do not understand and read Swedish or suffer from cognitive impairment, and informal caregivers with who need support or treatment that cannot be provided by Carer eSupport.

Contact & Investigator

Central Contact

Ylva Tiblom Ehrsson, Assoc prof

✉ ylva.tiblom.ehrsson@uu.se

📞 +46707747712

Principal Investigator

Ylva Tiblom Ehrsson, Assoc prof

PRINCIPAL INVESTIGATOR

Uppsala University

Frequently Asked Questions

Who can join the NCT06307418 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06307418 currently recruiting?

Yes, NCT06307418 is actively recruiting participants. Contact the research team at ylva.tiblom.ehrsson@uu.se for enrollment information.

Where is the NCT06307418 trial being conducted?

This trial is being conducted at Örebro, Sweden, Uppsala, Sweden, Umeå, Sweden, Gothenburg, Sweden.

Who is sponsoring the NCT06307418 clinical trial?

NCT06307418 is sponsored by Uppsala University. The principal investigator is Ylva Tiblom Ehrsson, Assoc prof at Uppsala University. The trial plans to enroll 110 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology